Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines
Posted 17th October 2018 by Kieran Chambers
Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.
Posted 15th October 2018 by Kate Barlow
Acne is the most common skin condition in the USA, affecting 85% of the world’s population over their lifetime and approximately 50 million people in the USA each year.
Posted 12th October 2018 by Laura Berry
Having a powerful set of tools is essential in life science research so we’ve compiled the best free platforms for genetic engineers, molecular and synthetic biologists.
Posted 10th October 2018 by Kieran Chambers
This article was originally published by Technology Networks in August 2018 and is published here with permission.
John Baldoni currently heads up a drug discovery unit at GlaxoSmithKline. Since joining GSK in 1989, John has held numerous positions within the company and has led many significant cross-functional strategic initiatives. He has an impressive 37 years’ experience working within the biopharmaceutical industry.
The recently established Accelerating Therapeutics for Opportunities in Medicine consortium, was conceived by John, with a mission “to accelerate the development of more effective therapies for patients”. ATOM stemmed from the Cancer Moonshot, an initiative that aims to improve the availability of cancer therapies, enhance detection of cancer early on, and improve our ability to prevent cancer.
Posted 8th October 2018 by Kate Barlow
Over recent years, we have seen record numbers of skin cancer diagnoses around the world. Indeed, since the 1980s, incidences of melanoma, the deadliest form of cancer, have doubled. Melanoma is an aggressive form of cancer that can spread to other organs and is estimated it will kill 10,000 people in the US this year. Approximately 3 million Americans will be diagnosed with skin cancer this year in the US.
Posted 5th October 2018 by Kate Barlow
There are currently more than 120 biobanks worldwide. While most focus on genomic research and personalised medicine, biobanks range in size. Small operations have just a few freezers which are kept in a researcher’s laboratory, a clinical laboratory, or a pathology suite, while the larger, commercial ones support large clinical and epidemiological suites. In addition, the storage of samples tends to vary:
Posted 3rd October 2018 by Kieran Chambers
Digital innovation in healthcare promises much. But potential and realisation are two very different things.
Researchers at Stanford in the US, for example, have developed an AI algorithm designed to diagnose skin cancer. AI diagnosis was compared with that of 21 dermatologists and it matched the efficacy of its human counterparts. This has significant implications for patients, particularly those who find it difficult to access healthcare professionals. But the implications don’t stop there.